Position in DNA
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$0
-$656,909 QoQ
Shares Held
0
-100.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2025
3 quarters on record
Common Shares in DNA Over Time
Shares Held
Position Value (USD)
Derivatives in DNA
reported options exposure · as of Jun 30, 2026CallValue
$1,619,294
CallShares
163,400
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Jun 30, 2026PEAK6 LLC holds $19,544,893 across 28 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TECH |
BIO-TECHNE Corp
|
67,942 | $4,800,102 | |
| 2 | IONS |
Ionis Pharmaceuticals Inc
|
29,460 | $2,335,883 | |
| 3 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
6,231 | $1,875,717 | |
| 4 | EDIT |
Editas Medicine, Inc.
|
415,441 | $1,346,028 | |
| 5 | BNTX |
BioNTech SE
|
13,584 | $1,263,991 | |
| 6 | CRSP |
CRISPR Therapeutics AG
|
22,316 | $1,217,114 | |
| 7 | ASND |
Ascendis Pharma A/S
|
3,764 | $1,003,934 | |
| 8 | RXRX |
Recursion Pharmaceuticals, Inc.
|
220,000 | $807,400 |
All Filings in DNA
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,619,294 | 163,400 | Call | Defined | 2026-08-13 | |
| 2026-03-31 | $656,909 | 107,163 | Shares | Defined | 2026-05-14 | |
| 2026-03-31 | $9,195 | 1,500 | Call | Defined | 2026-05-14 | |
| 2025-12-31 | $172,848 | 20,800 | Call | Defined | 2026-03-12 | |
| 2025-12-31 | $1,353,175 | 162,837 | Shares | Defined | 2026-03-12 | |
| No filing history on record for this holder in this stock. | ||||||